Novartis Investigation Confirms Conflict Of Interest in Diovan Trial; Japan Health Ministry Looking For More
This article was originally published in PharmAsia News
The third-party investigation into Japan trials of Diovan reveals no evidence of “willful manipulation” of data, but MHLW may look further into the trials.
You may also be interested in...
Some answers to industry questions about ambiguity in sunshine regulations may come through enforcement actions, Sidley Austin’s James Stansel says.
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.